Oventus Medical (ASX:OVN) has completed a share placement to institutional and sophisticated investors at $0.36 per share to raise circa $6.5 million.
A second tranche placement to raise a further $0.5 million will be conducted subject to shareholder approval being obtained at a general meeting to be held in August 2017.
The Brisbane-based medical device company is commercialising a suite of oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring.
Oventus’ O2Vent oral appliance is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.
Importantly, a clinical study completed earlier this year showed that the O2Vent is successful in treating OSA and that snoring was either eliminated or significantly reduced in 100% of
patients.
The company’s capital raising follows the recent signing of a global distribution agreement with Modern Dental Group.
Modern Dental Group is the world’s largest dental prosthetic device provider with over 70 sales and customer service centres covering North America, Europe, Australia, and China.
Oventus will use the new funds to increase working capital and build sales by co-marketing with distributor partners in various regions – in particular Modern Dental in the U.S. and Australia.
The company will also complete current clinical trials that will be used to further validate the value of the Oventus proprietary airway and engage with clinicians – especially sleep clinicians.
Oventus is also conducting a share purchase plan at $0.36 per share for eligible shareholders capped at $2 million.
The company’s shares closed 5.26% higher on Thursday, at $0.40.